Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 3Neoplasm Metastasis 2Mesothelioma, Malignant 2Disease Progression 2Small Cell Lung Carcinoma 1Sarcoma 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 134Carboplatin 129Bevacizumab 86Gemcitabine 45pembrolizumab 37olaparib 33Cisplatin 30liposomal doxorubicin 29Docetaxel 29Cyclophosphamide 29Topotecan 28niraparib 27Taxes 20Etoposide 18Filgrastim 16Doxorubicin 16Immunoglobulin G 15Disulfides 15apatinib 12Letrozole 12Albumin-Bound Paclitaxel 12Drug Therapy 11fluzoparib 10fludarabine 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 10durvalumab 9Nivolumab 9pazopanib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Neoplasms × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT03804866 2019-01-15

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

AGC Biologics S.p.A.

Phase 2 Completed
14 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT00484432 2018-09-27

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

AGC Biologics S.p.A.

Phase 2 Completed
37 enrolled
Gynecologic

Ovarian Neoplasms

NCT01358071 2018-09-27

NGR018

AGC Biologics S.p.A.

Phase 2 Completed
119 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡